<PAGE>
EXHIBIT 99.1
[NEXELL THERAPEUTICS INC. Nexell Therapeutics Inc.
LOGO APPEARS HERE] 9 Parker
Irvine, California
92618 1605
t.949 470 9011
f.949 586 2420
www.nexellinc.com
FOR IMMEDIATE RELEASE
---------------------
Contact: Tad Heitmann
Nexell Therapeutics Inc.
949-470-6516
NEXELL THERAPEUTICS ANNOUNCES PROMOTION OF
WILLIAM A. ALBRIGHT, JR., TO PRESIDENT AND COO
L. William McIntosh Will Leave Management Team
IRVINE, CA - July 12, 2000 - Nexell Therapeutics Inc. (NASDAQ:NEXL), one of the
world's leading suppliers of therapeutic and diagnostic products based on stem
cell technology, announced today the promotion of William A. Albright, Jr., to
President and COO. L. William McIntosh will leave the management team but
continue to advise the Company as a consultant and a member of the Board of
Directors.
"Bill McIntosh has been instrumental in building Nexell Therapeutics and has
guided our transition into a fully operational cell therapy company over the
last three years. Key milestones during his tenure include completing the
Baxter immunotherapy business unit and CellPro asset acquisitions, securing FDA
approval for the Isolex(R) 300i, and integrating worldwide distribution and
sales functions," said Richard L. Dunning, Chairman and CEO of Nexell
Therapeutics. "With this phase of our development complete, Bill will pursue
other opportunities as we continue our evolution into a highly successful
commercial enterprise."
"Since coming to Nexell Therapeutics Bill Albright led the effort to complete a
major financing last Fall and has also been intensively engaged on strategic,
operational and business development fronts," said Mr. Dunning. "Bill is well
suited to provide operational leadership to take the Company to the next level."
Mr. Albright has served as Senior Vice President and Chief Financial Officer of
Nexell Therapeutics since joining the Company in 1999. Over the last decade,
Mr. Albright held positions as Chief Financial Officer at several biomedical
companies including LocalMed, Inc., Connetics Corp., and ChemTrak, Inc. Prior
to that, he served as Director, Business Development, Finance and Administration
at Genta, Inc. and a Product Manager for medical disposables, at Eli Lilly &
Company, IVAC Corp., a pioneer in IV infusion systems. He holds Bachelors and
Masters of Biological Science degrees from Stanford University and a Masters of
Business Administration from Harvard University.
Nexell Therapeutics Inc.
Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq:NEXL) is a cell
therapy company whose mission is to put the healing power of the cell into the
hands of
<PAGE>
physicians. Nexell is developing and marketing innovative ex vivo cell
therapies and in vitro diagnostics for cancer, autoimmune, metabolic and genetic
diseases. Nexell's lead product, the Isolex(R) 300i Magnetic Cell Selection
System, is the only FDA approved device commercially available for the selection
of hematopoietic stem cells and the removal of tumor cells from autologous
peripheral blood as a component of aggressive cancer treatment. In addition,
Nexell markets the Cytonex(TM) ICC Staining Kit and an extensive line of cell
therapy preparation, storage and expansion products including the Cryocyte(TM),
SteriCell(R) and Lifecell(R) brands.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor"
for certain forward-looking statements. The forward-looking statements contained
in this release are subject to certain risks and uncertainties. Actual results
could differ materially from current expectations. Among the factors which could
affect the Company's actual results and could cause results to differ from those
contained in the forward-looking statements contained herein are: the timely
commencement and success of the Company's clinical trials and other research
endeavors, delays in receiving FDA or other regulatory approvals, the
development of competing therapies and/or technologies, the terms of any future
strategic alliances, the possible need for additional capital, and any
additional factors described from time to time in the Company's filings with the
SEC.
# # #
--------------------------------------------------------------------------------
NOTE TO INVESTORS AND EDITORS: Nexell Therapeutics Inc. press releases are
available on the Internet through www.nexellinc.com and through BusinessWire's
web site at http://www.businesswire.com. The releases are also available at no
charge through BusinessWire's fax-on-demand service at 800-411-8792.
--------------------------------------------------------------------------------
